Table 6.
Change in clinical diagnosis during the trial showing predictive validity of NNIPPS clinical diagnostic criteria in surviving patients
| Clinical diagnosis at inclusion | Final clinical diagnosis |
All | ||
|---|---|---|---|---|
| PSP | MSA | Other* | ||
| PSP | 246 (96%) | 2 (1%) | 8 (3%) | 256 |
| MSA | 13 (4%) | 270 (91%) | 15 (5%) | 298 |
| All | 259 | 272 | 23 | 554 |
* Other diagnosis: MSA (N = 15): IPD n = 7, ALS n = 2, CBD n = 3, LBD n = 1, Carbon dioxide intox n = 1, MPI multilacunar n = 1; PSP (N = 8): Mixed PSP/MSA n = 1, Lower body Parkinsonism – pseudo PSP n = 1, CBD n = 1, FTDP or Motor neuron disease n = 1, ophthalmoplegia n = 1, FTD n = 1, multiple cerebral infarct n = 1, unidentified n = 1.